ClinicalTrials.gg
CompletedNCT01476787RELEVANCEUpdated May 14, 2025Results posted

Combined Rituximab and Lenalidomide Treatment for Untreated Patients With Follicular Lymphoma

A Phase 3 interventional study of Rituximab and Lenalidomide in Follicular Lymphoma, sponsored by Celgene. Completed at 36 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-14.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,030
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 194 studies testing rituximab in Lymphoma, Follicular — 12 open to participants now, 24 under way, 6 of them phase 3. Rituximab · Lymphoma, Follicular.

Enrollment
3rd of 188
1,030 · median 48
Started
2011
with 8 others
Phase 3
35 of 194
2 open now
Registered
139th of 194
by date

Among the 194 studies testing rituximab in Lymphoma, Follicular, this one is the 3rd largest by enrollment of the 188 interventional ones that give a count, is one of 9 that started in 2011, is one of 35 in phase 3, and was the 139th registered.

Lymphoma, Follicular

1,891 studies on the registry are indexed under Lymphoma, Follicular; 289 are open to participants now.

Browse Lymphoma, Follicular studies →

Open to participants now

12 of the 194 studies testing rituximab in Lymphoma, Follicular are open now, in 12 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About rituximab

Rituximab: first FDA approval 1997 (RITUXAN), first EMA approval 1998. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 225 Lymphoma, Follicular studies recruiting now, 158 (70%) set no upper age limit and 39 (17%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 194 studies testing rituximab in Lymphoma, Follicular, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effect of the combined treatment of lenalidomide and rituximab in controlling the Follicular Lymphoma disease and also increase the length of response compared to the available standard combination chemotherapy treatment for Follicular Lymphoma.

Read the detailed description

Follicular Lymphoma (FL) is a cancer of a B lymphocyte, a type of white blood cell. FL is typically a slowly progressing but incurable disease. Follicular lymphoma cells produce a specific defect in the patient's immune system impairing their ability to control their cancer. Lenalidomide has been shown to reverse the specific immune defect caused by FL in the patient. By including lenalidomide, the RELEVANCE study aims to eliminate the cancer while restoring the patient's immune competence.

The 'Relevance' cooperative group trial is being conducted as two companion studies: RV-FOL-GELARC-0683 (N=750) and RV-FOL-GELARC-0683C (N=250); the combined total of 1000 Follicular Lymphoma patients enrolled in both studies will be analyzed.

03

Conditions studied

  • Follicular Lymphoma

Keywords

  • Follicular lymphoma
  • Non-Hodgkins Follicular Lymphoma
  • treatment for Follicular Lymphoma
  • rituximab treatment
  • rituximab and lenalidomide treatment
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed follicular lymphoma grade 1, 2 or 3a, Stage II-IV
  • Have no prior systemic treatment for lymphoma
  • Symptomatic follicular lymphoma requiring treatment.
  • Age ≥18 years
  • performance status 0-2
  • Willing to follow pregnancy precautions

Exclusion criteria

Exclusion Criteria:

  • Clinical evidence of transformed lymphoma or Grade 3b follicular lymphoma.
  • Major surgery (excluding lymph node ) within 28 days prior to signing .
  • Known seropositive for or active viral infection with virus (HBV), virus (HCV), (HIV)
  • Known sensitivity or allergy to murine products.
  • Presence or history of central nervous system involvement by lymphoma
  • At high risk for a venous thromboembolic event (VTE) and not willing to take VTE prophylaxis
  • Any of the following laboratory abnormalities:
  • serum or alanine transaminase > 3x (ULN), except in patients with documented liver involvement by lymphoma
  • total > 2.0 mg/dl (34 µmol/L) except in cases of Gilberts Syndrome and documented liver or pancreatic involvement by lymphoma
  • of \< 30 mL/min
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,030 participants (actual)

Study arms

  • Experimental
    Lenalidomide + Rituximab

    * Lenalidomide dose 20-mg on days 2-22 every 28 days for 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for up to 18 cycles. * Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

    Drug: Rituximab · Drug: Lenalidomide

  • Active comparator
    Control

    • ONE of the following: Rituximab-CHOP, Rituximab-CVP, Rituximab-Bendamustine. 7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

    Drug: Rituximab-CHOP · Drug: Rituximab-CVP · Drug: Rituximab-Bendamustine

Interventions

  • 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3\~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles

    Also known as: Revlimid

  • DrugRituximab-CHOP

    7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • DrugRituximab-CVP

    7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

  • DrugRituximab-Bendamustine

    7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.

06

What researchers measure

Primary outcomes

  1. Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review

    The Complete Response Rate (CR/CRu) is the percentage of participants who achieve complete response (CR/CRu) at 120 weeks as assessed per Independent Central Review. * Complete Response (CR): Disappearance of all evidence of disease. * Complete Response Unconfirmed (CRu): Disappearance of all disease with the exception of residual lymph nodes that are 1.5 cm or less in greatest transverse diameter and/or indeterminate bone marrow findings.

    Time frame: At 120 weeks

  2. Progression-free Survival (PFS)

    Progression-free survival (PFS) is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause. Progressive Disease (PD) is characterized by any of the following: * An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites. * The appearance of any new lesion during or after treatment. * An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis. * An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly). Based on Kaplan-Meier estimates.

    Time frame: From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).

Secondary outcomes

  1. Complete Response Rate (CR) at 120 Weeks Per Independent Central Review

    The Complete Response Rate (CR) is the percentage of participants who achieve confirmed complete response (CR) at 120 weeks as assessed per Independent Central Review. - Complete Response (CR): Disappearance of all evidence of disease.

    Time frame: At 120 weeks

  2. Event-free Survival (EFS)

    Event Free Survival (EFS) is defined as the time a participant remains free from certain negative events (disease progression, relapse, initiation of a new anti-lymphoma treatment, or death) between the date of randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause. Responding participants and those lost to follow up were censored at their last tumor assessment date. Progressive Disease (PD) is characterized by any of the following: * An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites. * The appearance of any new lesion during or after treatment. * An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis. * An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly). Based on Kaplan-Meier estimates.

    Time frame: From randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause (up to approximately 140 months).

  3. Overall Survival (OS)

    Overall survival (OS) is defined as the median length of time a participant stays alive from randomization. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who withdrew consent for the study were considered censored at the time of withdrawal. Participants who completed the study and were still alive at the time of the clinical data cut-off date were censored. All participants who were lost to follow-up prior to the clinical data cut-off date were also considered censored at the time of last contact. Based on Kaplan-Meier estimates.

    Time frame: From randomization to the date of death by any cause (up to approximately 144 months).

  4. Time to Next Anti-Lymphoma Treatment (TTNLT)

    Time to Next Lymphoma Treatment (TTNLT) was measured from the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (such as chemotherapy, radiotherapy, radio-immunotherapy, or immunotherapy). Participants who continued to respond to treatment or who were lost to follow-up were considered censored on their last visit date. Participants who died (due to any cause) before receiving a new anti-lymphoma treatment were included in the statistical analysis, with death being counted as an event. Based on Kaplan-Meier estimates.

    Time frame: From the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (up to approximately 140 months).

07

Results

Posted May 14, 2025

Participant flow

Pre-treatment
Participant flow — Pre-treatment
MilestoneRituximab-LenalidomideInvestigator Choice
Started513517
Completed507503
Not completed614
Treatment
Participant flow — Treatment
MilestoneRituximab-LenalidomideInvestigator Choice
Started507503
Completed350357
Not completed157146
Withdrew: Progression6471
Withdrew: Toxicity4416
Withdrew: Death01
Withdrew: Withdrawal by subject314
Withdrew: Major protocol violation16
Withdrew: Other reasons1022
Withdrew: Concurrent illness129
Withdrew: Insufficient response153
Withdrew: Voluntary treatment discontinuation84

Outcome measures

PrimaryComplete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review

The Complete Response Rate (CR/CRu) is the percentage of participants who achieve complete response (CR/CRu) at 120 weeks as assessed per Independent Central Review. * Complete Response (CR): Disappearance of all evidence of disease. * Complete Response Unconfirmed (CRu): Disappearance of all disease with the exception of residual lymph nodes that are 1.5 cm or less in greatest transverse diameter and/or indeterminate bone marrow findings.

Time frame:
At 120 weeks
Reported as:
Number · Percent of participants
Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review
Percent of participantsRituximab-LenalidomideInvestigator Choice
Complete Response Rate (CR/CRu) at 120 Weeks by Independent Central Review48.1 (43.7 to 52.6)53.0 (48.6 to 57.4)
Statistical analysis
  • Rituximab-Lenalidomide vs Investigator Choice · Cochran-Mantel-Haenszel · p = 0.128
PrimaryProgression-free Survival (PFS)

Progression-free survival (PFS) is defined as the time from randomization into the study to the first observation of documented disease progression or death due to any cause. Progressive Disease (PD) is characterized by any of the following: * An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites. * The appearance of any new lesion during or after treatment. * An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis. * An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly). Based on Kaplan-Meier estimates.

Time frame:
From randomization into the study to the first observation of documented disease progression or death due to any cause (up to approximately 140 months).
Reported as:
Median · Months
Progression-free Survival (PFS)
MonthsRituximab-LenalidomideInvestigator Choice
Progression-free Survival (PFS)120.2 (104.9 to 126.3)123.8 (107.4 to NA)
Statistical analysis
  • Rituximab-Lenalidomide vs Investigator Choice · Log Rank · p = 0.406 · Hazard ratio (hr): 0.920 · 95% CI 0.756 to 1.120
SecondaryComplete Response Rate (CR) at 120 Weeks Per Independent Central Review

The Complete Response Rate (CR) is the percentage of participants who achieve confirmed complete response (CR) at 120 weeks as assessed per Independent Central Review. - Complete Response (CR): Disappearance of all evidence of disease.

Time frame:
At 120 weeks
Reported as:
Number · Percent of participants
Complete Response Rate (CR) at 120 Weeks Per Independent Central Review
Percent of participantsRituximab-LenalidomideInvestigator Choice
Complete Response Rate (CR) at 120 Weeks Per Independent Central Review27.7 (23.8 to 31.8)32.7 (28.7 to 36.9)
SecondaryEvent-free Survival (EFS)

Event Free Survival (EFS) is defined as the time a participant remains free from certain negative events (disease progression, relapse, initiation of a new anti-lymphoma treatment, or death) between the date of randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause. Responding participants and those lost to follow up were censored at their last tumor assessment date. Progressive Disease (PD) is characterized by any of the following: * An increase of at least 50% in the sum of the products of the greatest diameters (SPD) of any previously identified abnormal lymph node(s) or other disease sites. * The appearance of any new lesion during or after treatment. * An increase of at least 50% in the longest diameter of a previously identified node that was 1 cm or more in its short axis. * An increase of at least 50% in the size of other lesions (e.g., splenomegaly, hepatomegaly). Based on Kaplan-Meier estimates.

Time frame:
From randomization to the date of first documented progression, relapse, and initiation of a new anti-lymphoma treatment or death by any cause (up to approximately 140 months).
Reported as:
Median · Months
Event-free Survival (EFS)
MonthsRituximab-LenalidomideInvestigator Choice
Event-free Survival (EFS)130.6 (121.9 to NA)132.3 (115.7 to NA)
Statistical analysis
  • Rituximab-Lenalidomide vs Investigator Choice · Hazard ratio (hr): 1.038 · 95% CI 0.854 to 1.261
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the median length of time a participant stays alive from randomization. Participants who died, regardless of the cause of death, were considered to have had an event. Participants who withdrew consent for the study were considered censored at the time of withdrawal. Participants who completed the study and were still alive at the time of the clinical data cut-off date were censored. All participants who were lost to follow-up prior to the clinical data cut-off date were also considered censored at the time of last contact. Based on Kaplan-Meier estimates.

Time frame:
From randomization to the date of death by any cause (up to approximately 144 months).
Reported as:
Median · Months
Overall Survival (OS)
MonthsRituximab-LenalidomideInvestigator Choice
Overall Survival (OS)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Rituximab-Lenalidomide vs Investigator Choice · Hazard ratio (hr): 1.040 · 95% CI 0.775 to 1.395
SecondaryTime to Next Anti-Lymphoma Treatment (TTNLT)

Time to Next Lymphoma Treatment (TTNLT) was measured from the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (such as chemotherapy, radiotherapy, radio-immunotherapy, or immunotherapy). Participants who continued to respond to treatment or who were lost to follow-up were considered censored on their last visit date. Participants who died (due to any cause) before receiving a new anti-lymphoma treatment were included in the statistical analysis, with death being counted as an event. Based on Kaplan-Meier estimates.

Time frame:
From the date of randomization to the date of the first documented administration of any new anti-lymphoma treatment (up to approximately 140 months).
Reported as:
Median · Months
Time to Next Anti-Lymphoma Treatment (TTNLT)
MonthsRituximab-LenalidomideInvestigator Choice
Time to Next Anti-Lymphoma Treatment (TTNLT)NA (NA to NA)NA (NA to NA)
Statistical analysis
  • Rituximab-Lenalidomide vs Investigator Choice · Regression, Cox · Hazard ratio (hr): 0.809 · 95% CI 0.651 to 1.006

Adverse events

Collected over Participants were assessed for all-cause mortality from randomization to study completion (up to approximately 144 months). SAEs and Other AEs were assessed from first dose to 28 days post the last dose (up to approximately an average of 25 months and a maximum of 33 months).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rituximab-Lenalidomide88/513 (17.2%)181/507 (35.7%)496/507 (97.8%)
Investigator Choice Rituximab-CHOP71/372 (19.1%)109/365 (29.9%)351/365 (96.2%)
Investigator Choice Rituximab-CVP7/28 (25%)7/26 (26.9%)26/26 (100%)
Investigator Choice Rituximab-Bendamustine12/117 (10.3%)32/112 (28.6%)108/112 (96.4%)
Most frequent serious events
Showing 10 of 304
Most frequent serious events
EventRituximab-LenalidomideInvestigator Choice Rituximab-CHOPInvestigator Choice Rituximab-CVPInvestigator Choice Rituximab-Bendamustine
FEBRILE NEUTROPENIABlood and lymphatic system disorders9/50717/3651/266/112
SQUAMOUS CELL CARCINOMA OF SKINNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/5071/3651/266/112
CARDIAC FAILURECardiac disorders1/5070/3651/260/112
GASTRITISGastrointestinal disorders0/5070/3651/260/112
INTESTINAL OBSTRUCTIONGastrointestinal disorders1/5071/3651/260/112
CHEST PAINGeneral disorders2/5072/3651/260/112
OEDEMA PERIPHERALGeneral disorders1/5070/3651/260/112
INFLUENZAInfections and infestations1/5072/3651/260/112
LARGE INTESTINE INFECTIONInfections and infestations0/5071/3651/260/112
SINUSITISInfections and infestations0/5070/3651/260/112
Most frequent other events
Showing 10 of 75
Most frequent other events
EventRituximab-LenalidomideInvestigator Choice Rituximab-CHOPInvestigator Choice Rituximab-CVPInvestigator Choice Rituximab-Bendamustine
FATIGUEGeneral disorders116/50767/3656/2673/112
NAUSEAGastrointestinal disorders100/507128/3657/2672/112
CONSTIPATIONGastrointestinal disorders179/507109/36513/2643/112
NEUTROPENIABlood and lymphatic system disorders199/507172/3657/2625/112
DIARRHOEAGastrointestinal disorders184/50750/3656/2637/112
ASTHENIAGeneral disorders144/507129/3656/265/112
RASHSkin and subcutaneous tissue disorders141/50722/3651/2619/112
VOMITINGGastrointestinal disorders32/50761/3652/2631/112
INFUSION RELATED REACTIONInjury, poisoning and procedural complications58/50725/3651/2629/112
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations48/50722/3655/2628/112

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Rituximab-LenalidomideInvestigator ChoiceTotal
Mean58.5 ± 11.2358.3 ± 11.3858.4 ± 11.30
Sex: Female, Male
Sex: Female, Male(Participants)Rituximab-LenalidomideInvestigator ChoiceTotal
Female262266528
Male251251502
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)Rituximab-LenalidomideInvestigator ChoiceTotal
Count of participants——0
08

Study locations

36 sites
  • Local Institution - 54103
    Chandler, Arizona 85224, United States
  • Local Institution - 51803
    Fullerton, California 92835, United States
  • Local Institution - 52003
    Los Angeles, California 90095, United States
  • Local Institution - 51603
    Colorado Springs, Colorado 80909, United States
  • Local Institution - 52503
    Englewood, Florida 34223, United States
  • Local Institution - 51703
    Orlando, Florida 32806, United States
  • Local Institution - 53803
    Saint Petersburg, Florida 33705, United States
  • Local Institution - 50803
    Chicago, Illinois 60657, United States
  • Local Institution - 52203
    Lexington, Kentucky 40536, United States
  • Local Institution - 53603
    Westminster, Maryland 21157, United States
  • Local Institution - 50403
    Boston, Massachusetts 02114, United States
  • Local Institution - 50503
    Boston, Massachusetts 02114, United States
  • Local Institution - 53003
    Southfield, Michigan 48075, United States
  • Local Institution - 51003
    Saint Louis, Missouri 63110, United States
  • Local Institution - 54403
    Cherry Hill, New Jersey 08003, United States
  • Local Institution - 53703
    Hackensack, New Jersey 07601, United States
  • Local Institution - 50903
    Morristown, New Jersey 07960, United States
  • Local Institution - 54303
    Sparta, New Jersey 07871, United States
  • Local Institution - 52403
    New York, New York 10019, United States
  • Local Institution - 50203
    New York, New York 10021, United States
  • Local Institution - 51303
    Nashville, Tennessee 37203, United States
  • Local Institution - 51203
    Dallas, Texas 75246, United States
  • Local Institution - 51103
    Houston, Texas 77030, United States
  • Local Institution - 54003
    Lubbock, Texas 79410, United States
  • Local Institution - 53303
    Richmond, Virginia 23230, United States
  • Local Institution - 52703
    Seattle, Washington 98109, United States
  • Local Institution - 40722
    Chuo-ku, Tokyo 104-0045, Japan
  • Local Institution - 40222
    Koto-ku, Tokyo 1358550, Japan
  • Local Institution - 41122
    Minato-ku, Tokyo 105-8470, Japan
  • Local Institution - 40922
    Fukuoka, 812-8582, Japan
  • Local Institution - 40422
    Hiroshima, 7200001, Japan
  • Local Institution - 40122
    Isehara City, Kanagawa, 259-1193, Japan
  • Local Institution - 40322
    Kobe-city, 650-0047, Japan
  • Local Institution - 40622
    Kyoto-city, 602-8566, Japan
  • Local Institution - 41022
    Sendai-city, 983-8520, Japan
  • Local Institution - 40522
    Shizuoka, 410-2295, Japan
09

References and documents

Publications

  • Morschhauser F, Fowler NH, Feugier P, Bouabdallah R, Tilly H, Palomba ML, Fruchart C, Libby EN, Casasnovas RO, Flinn IW, Haioun C, Maisonneuve H, Ysebaert L, Bartlett NL, Bouabdallah K, Brice P, Ribrag V, Daguindau N, Le Gouill S, Pica GM, Martin Garcia-Sancho A, Lopez-Guillermo A, Larouche JF, Ando K, Gomes da Silva M, Andre M, Zachee P, Sehn LH, Tobinai K, Cartron G, Liu D, Wang J, Xerri L, Salles GA; RELEVANCE Trial Investigators. Rituximab plus Lenalidomide in Advanced Untreated Follicular Lymphoma. N Engl J Med. 2018 Sep 6;379(10):934-947. doi: 10.1056/NEJMoa1805104. PubMed 30184451 ↗
  • Fowler NH, Davis RE, Rawal S, Nastoupil L, Hagemeister FB, McLaughlin P, Kwak LW, Romaguera JE, Fanale MA, Fayad LE, Westin JR, Shah J, Orlowski RZ, Wang M, Turturro F, Oki Y, Claret LC, Feng L, Baladandayuthapani V, Muzzafar T, Tsai KY, Samaniego F, Neelapu SS. Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial. Lancet Oncol. 2014 Nov;15(12):1311-8. doi: 10.1016/S1470-2045(14)70455-3. Epub 2014 Oct 15. PubMed 25439689 ↗
  • Ahmadi T, Chong EA, Gordon A, Aqui NA, Nasta SD, Svoboda J, Mato AR, Schuster SJ. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas. Cancer. 2014 Jan 15;120(2):222-8. doi: 10.1002/cncr.28405. Epub 2013 Oct 7. PubMed 24122387 ↗
  • Delfau-Larue MH, Boulland ML, Beldi-Ferchiou A, Feugier P, Maisonneuve H, Casasnovas RO, Lemonnier F, Pica GM, Houot R, Ysebaert L, Tilly H, Eisenmann JC, Le Gouill S, Ribrag V, Godmer P, Glaisner S, Cartron G, Xerri L, Salles GA, Fest T, Morschhauser F. Lenalidomide/rituximab induces high molecular response in untreated follicular lymphoma: LYSA ancillary RELEVANCE study. Blood Adv. 2020 Aug 11;4(14):3217-3223. doi: 10.1182/bloodadvances.2020001955. PubMed 32673385 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2011 to primary completion in Apr 2024, 148 months.

Results were first posted in May 2025, 1 year after primary completion.

Of 45 industry-sponsored phase 3 interventional studies under Lymphoma, Follicular, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 86. This study's 148 months is above that.

Counting every sponsor, half of 80 studies reached it within 63 months; a quarter within 36 and three quarters within 106.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2011
First posted
Nov 22, 2011
StartActual
Dec 29, 2011
Primary completionActual
Apr 30, 2024
CompletionActual
Apr 30, 2024
Results first posted
May 14, 2025
Last update
May 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01476787
Lead sponsor
Celgene
Collaborators
The Lymphoma Academic Research Organisation
Responsible party
Sponsor
First posted
Nov 22, 2011
Start date
Dec 29, 2011
Primary completion
Apr 30, 2024
Completion
Apr 30, 2024
Results posted
May 14, 2025
Last update
May 14, 2025

Study contacts

Franck Morschhauser, MD, PhD
study chair · The Lymphoma Study Association (LYSA)

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Rituximab · Lenalidomide

Start the discussion